Cardiovascular Risk in Prostate Cancer.

Autor: Leong DP; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada; Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Canada. Electronic address: darryl.leong@phri.ca., Cirne F; Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Canada., Pinthus JH; Division of Urology, Department of Surgery, McMaster University, Hamilton, Canada.
Jazyk: angličtina
Zdroj: Cardiology clinics [Cardiol Clin] 2025 Feb; Vol. 43 (1), pp. 83-91. Date of Electronic Publication: 2024 Oct 05.
DOI: 10.1016/j.ccl.2024.09.003
Abstrakt: Cardiovascular disease is common in patients with prostate cancer and is an important cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy (ADT) reduces muscle strength and increases adiposity, thereby increasing the risk of diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor signaling inhibitors and CYP17A1 inhibitors may confer incremental risks of hypertension and cardiovascular events to ADT. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists as compared with agonists requires prespecified randomized clinical trial confirmation.
Competing Interests: Disclosure D.P. Leong reports consultancy fees or advisory boards from Abbvie, Ipsen, Janssen, Jazz Pharmaceuticals, Myovant, Novartis, Sanofi, Antev, Bayer, Boston Scientific; speaker fees from Ferring, Pfizer, AstraZeneca; and research grants from Tolmar and Novartis. J.H. Pinthus reports consultancy fees or advisory boards from Ferring, Myovant and Antev; speaker fees from Ferring and research grants from Ferring. F. Cirne has no disclosures.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: